Results 61 to 70 of about 1,218 (152)

Interrelationship Between Baseline HbA1c, SGLT‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.
ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu, Setor K. Kunutsor, Erwin Taguiam, Kamlesh Khunti   +3 more
wiley   +1 more source

NetMetaEasy: enabling rapid and user‐friendly network meta‐analysis (NMA) for comparative effectiveness research

British Journal of Pharmacology, Volume 183, Issue 9, Page 1814-1823, May 2026.
Background and Purpose Network meta‐analysis (NMA) enables the simultaneous comparison of multiple treatments by combining direct and indirect evidence across a network of studies. While its application is rapidly expanding in pharmacological research and clinical guideline development, performing NMA typically requires advanced statistical knowledge ...
János Tibor Fekete, András Komócsi, Balázs Győrffy   +2 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Correspondence: Effects of short‐term tofogliflozin treatment on insulin secretory capacity in type 2 diabetes: Insights and future directions

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1440-1441, August 2026.
Gargi Bisht, Nitin Kumar Indora
wiley   +1 more source

Boscisucrophage: A Natural SGLT1/2 Inhibitor From Boscia senegalensis for Managing Type 2 Diabetes

Food Science &Nutrition, Volume 14, Issue 3, March 2026.
Boscisucrophage (BSP) significantly reduced blood glucose and HbA1c, increased urine glucose excretion, and improved functional symptoms in T2DM patients resistant to oral antihyperglycemic drugs. BSP showed no adverse effects on liver or kidney function.
Bruno Eto, Amal Elrherabi, Fahd A. Nasr, Joe Miantezila Basilua, Ahlam Outman, Rosette Christelle Ndjip, Mohamed Bouhrim, Mohammed Al‐zharani, Ashraf Ahmed Qurtam, Brahim Ibet, Bernard Gressier, Jehan‐François Desjeux   +11 more
wiley   +1 more source

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, Volume 6, Issue 1, Page 7-15, March 2026.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model

Frontiers in Pharmacology, 2014
Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin and canagliflozin, have already been approved for use in USA and Europe; several ...
Oleg eDemin Jr, Tatiana eYakovleva, Dmitry eKolobkov, Oleg eDemin   +3 more
doaj   +1 more source

Issue Information

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1243-1246, August 2026.
wiley   +2 more sources

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Journal of Pharmacological Sciences, 2016
The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing hyperglycaemia via increased urinary glucose excretion.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki   +4 more
doaj   +1 more source

Correction to “Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP‐2ELM study”

Journal of Diabetes Investigation, EarlyView.
wiley   +1 more source